Levoflox GPO

Levoflox GPO

levofloxacin

Manufacturer:

GPO

Distributor:

GPO
Concise Prescribing Info
Contents
Levofloxacin
Indications/Uses
Mild, moderate & severe infections caused by susceptible strains of the designated microorganisms in: Acute sinusitis due to Strep pneumoniae, Haemophilus influenzae or Moraxella catarrhalis; acute exacerbation of chronic bronchitis due to Staph aureus, Strep pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae or Moraxella catarrhalis; community-acquired pneumonia due to Staph aureus, Strep pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophilia or Mycoplasma pneumoniae; nosocomial pneumonia due to methicillin-susceptible Staph aureus, Pseudomonas aeruginosa, Serratia marcescens, E. coli, Klebsiella pneumoniae, Haemophilus influenzae or Strep pneumoniae; uncomplicated skin & skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections due to Staph aureus & Strep pyogenes; complicated skin & skin structure infection (mild to moderate)  due to methicillin-susceptible Staph aureus, Enterococcus faecalis, Strep pyogenes or Proteus mirabilis; UTI (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, E. coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, or Staph saprophyticus; chronic bacterial prostatitis due to E. coli, Enterococcus faecalis or Staph epidermidis; pyelonephritis (mild to moderate) caused by E. coli; empirical treatment of community-acquired pneumonia most likely caused by organisms susceptible to levofloxacin.
Dosage/Direction for Use
Empirical treatment of community-acquired pneumonia 500 or 750 mg once daily. Acute sinusitis 500 or 750 mg every 24 hr for 10-14 or 5 days, respectively. Acute exacerbation of chronic bronchitis 500 mg every 24 hr for 7 days. Community-acquired pneumonia 500 or 750 mg every 24 hr for 7-14 or 5 days, respectively. Nosocomial pneumonia 750 mg every 24 hr for 7-14 days. Uncomplicated skin & skin structure infection 500 mg every 24 hr for 7-10 days. Complicated skin & skin structure infection 750 mg every 24 hr for 7-14 days. Chronic bacterial prostatitis 500 mg every 24 hr for 28 days. Complicated UTI 250 mg every 24 hr for 10 days. Uncomplicated UTI 250 mg every 24 hr for 3 days. Pyelonephritis 250 mg every 24 hr for 10 days. Impaired renal function Acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, uncomplicated skin & skin structure infections, chronic bacterial prostatitis CrCl 20-49 mL/min Initially 500 mg followed by 250 mg every 24 hr, CrCl 10-19 mL/min Initially 500 mg followed by 250 mg every 48 hr, hemodialysis Initially 500 mg followed by 250 mg every 48 hr, continuous ambulatory peritoneal dialysis Initially 500 mg followed by 250 mg every 48 hr. Complicated skin & skin structure, nosocomial pneumonia, community-acquired pneumonia CrCl 20-49 mL/min Initially 750 mg followed by 750 mg every 48 hr, CrCl 10-19 mL/min Initially 750 mg followed by 500 mg every 48 hr, hemodialysis Initially 750 mg followed by 500 mg every 48 hr, continuous ambulatory peritoneal dialysis Initially 750 mg every 500 mg every 48 hr. Complicated UTI, pyelonephritis CrCl 10-19 mL/min Initially 250 mg followed by 250 mg every 48 hr.  
Administration
May be taken with or without food: Ensure adequate fluid intake.
Contraindications
Epilepsy. Childn <18 yr. May cause arthropathy & osteochondrosis.
Special Precautions
Patients w/ impaired renal function, exposed to direct sunlight, known or suspected CNS disorder, diabetes (receiving oral hypoglycemic agent or w/ insulin). Ensure adequate hydration. Monitor blood glucose of diabetics. Discontinue use if hypoglycemia occurs. Pseudomembranous colitis-associated diarrhea. Tendinitis. False-negative results in diagnosis of TB. May impair ability to drive or operate machinery. Elderly.
Adverse Reactions
Nausea, diarrhea, increased liver enzymes (eg, ALT, AST). Anorexia, vomiting, abdominal pain, dyspepsia. Headache, dizziness/vertigo, drowsiness, insomnia. Pruritus, rash. Increased bilirubin & serum creatinine. Eosinophilia, leukopenia. Asthenia, fungal overgrowth & proliferation of other resistance microorganisms.
Drug Interactions
GI absorption may be interfered w/ antacids containing Al & Mg, sucralfate, metal cations eg, Fe & multivit prep w/ Zn. Pronounced lowering of cerebral seizure threshold w/ theophylline or fenbufen. Disturbance in blood glucose including hyperglycemia & hypoglycemia w/ antidiabetic agents.
MIMS Class
ATC Classification
J01MA12 - levofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Presentation/Packing
Form
Levoflox GPO FC tab 500 mg
Packing/Price
10 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in